Rnaset2 compositions and methods of treatment therewith
AssigneeCedars-Sinai Medical Center
InventorsRebecca GONSKY, Stephan R. TARGAN
Life of this patent
Estimating the term…
Abstract
Described herein are methods, systems, compositions, and kits useful for the diagnosis and/or treatment of a disease or condition in a subject. The present disclosure relates to methods and systems for identifying and stratifying patients suitable for treatment with a modulator of RNASET2, as described herein.
Claims24
-9. (canceled)
A method of increasing or enhancing activity or expression of Ribonuclease T2 (RNASET2) in a subject, the method comprising administering a modulator of RNASET2 activity or expression to the subject, provided a genotype comprising Indel 1 is detected in a sample obtained from the subject.
(canceled)
(canceled)
A method of decreasing activity or expression of tumor necrosis factor-like protein 1 (TL1A) in a subject, the method comprising administering an inhibitor of TL1A activity or expression to the subject, provided a genotype comprising Indel 1 is detected in a sample obtained from the subject.
(canceled)
(canceled)
A polypeptide comprising a first amino acid sequence and a second amino acid sequence of an Fc, wherein the first amino acid sequence is 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, or 90% homologous to at least 50 contiguous amino acids provided in SEQ ID NO:
- 11;
- optionally wherein the second amino acid of an Fc comprises a human IgG Fc.
Dependencies are inferred from the claim text.